Stanley Hsia is an Endocrinology/Metabolic physician affiliated with Velocity Clinical Research. OpenAlex indexes 53 publications with 3,682 citations (h-index 21); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12021 Wilmington Ave
Los Angeles, CA 900593019
Telephone
909-919-9296Registry record last updated 8 Jul 2007.
Clinical trials
- Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus
Sponsor: Charles Drew University of Medicine and Science
- Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
Sponsor: Charles Drew University of Medicine and Science
- Insulin Resistance in Smokers Undergoing Smoking Cessation
Sponsor: Charles Drew University of Medicine and Science
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202510 payments
- Amgen Inc.Program year20255 payments
- Madrigal PharmaceuticalsProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2005–2019 per NIH RePORTER. The latest:
- Pilot Study of the Efficacy of Mifepristone in Males with Type 2 Diabetes Mellitu
Charles R. Drew University of Med & Sci
FY2019$107,625SC3GM113767 - Pilot Study of the Efficacy of Mifepristone in Males with Type 2 Diabetes Mellitu
Charles R. Drew University of Med & Sci
FY2018$107,625SC3GM113767 - Pilot Study of the Efficacy of Mifepristone in Males with Type 2 Diabetes Mellitu
Charles R. Drew University of Med & Sci
FY2017$107,625SC3GM113767
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
Annals of Internal Medicine
2026 - Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
New England Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”